Antimalarial effects of human immunodeficiency virus type 1 protease inhibitors differ from those of the aspartic protease inhibitor pepstatin

Sunil Parikh, Jun Liu, Puran Sijwali, Jiri Gut, Daniel E. Goldberg, Philip J. Rosenthal

Research output: Contribution to journalArticle

30 Scopus citations

Abstract

Human immunodeficiency virus type 1 protease inhibitors (HIVPIs) and pepstatin are aspartic protease inhibitors with antimalarial activity. In contrast to pepstatin, HIVPIs were not synergistic with a cysteine protease inhibitor or more active against parasites with the cysteine protease falcipain-2 knocked out than against wild-type parasites. As with pepstatin, HIVPIs were equally active against wild-type parasites and against parasites with the food vacuole plasmepsin aspartic proteases knocked out. The antimalarial mechanism of HIVPIs differs from that of pepstatin.

Original languageEnglish
Pages (from-to)2207-2209
Number of pages3
JournalAntimicrobial agents and chemotherapy
Volume50
Issue number6
DOIs
StatePublished - Jun 1 2006

Fingerprint Dive into the research topics of 'Antimalarial effects of human immunodeficiency virus type 1 protease inhibitors differ from those of the aspartic protease inhibitor pepstatin'. Together they form a unique fingerprint.

  • Cite this